Candida infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:50 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Candida infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Rezafungin Levels in Critically Ill Patients with Invasive Candidiasis Undergoing ECMO or RRT https://clinicaltrials.eu/trial/study-on-rezafungin-levels-in-critically-ill-patients-with-invasive-candidiasis-undergoing-ecmo-or-rrt/ Wed, 29 Apr 2026 15:04:37 +0000 https://clinicaltrials.eu/trial/study-on-rezafungin-levels-in-critically-ill-patients-with-invasive-candidiasis-undergoing-ecmo-or-rrt/ This clinical trial is focused on studying a serious fungal infection known as invasive candidiasis. This condition can occur in critically ill patients, particularly those receiving advanced medical support like extracorporeal membrane oxygenation (ECMO) or renal replacement therapy (RRT). The treatment being investigated is a medication called Rezafungin, which is part of a group of antifungal medicines known as echinocandins. Rezafungin is administered as a solution through an intravenous infusion, meaning it is given directly into the bloodstream.

The purpose of this study is to evaluate how Rezafungin behaves in the body of patients who are receiving ECMO, with or without RRT. This includes understanding how the drug is absorbed, distributed, and eliminated from the body. The study will monitor the levels of Rezafungin in the blood to gather this information. Patients participating in the study will receive Rezafungin as part of their treatment for invasive candidiasis, and their response to the medication will be closely observed.

Throughout the study, researchers will also look at how different factors, such as additional medical treatments, body weight, and gender, might affect the levels of Rezafungin in the blood. Additionally, any side effects experienced by patients will be recorded, as well as any reasons for stopping the treatment. The study aims to provide valuable insights into the use of Rezafungin in critically ill patients, helping to improve treatment strategies for those with invasive candidiasis.

]]>